Cyclopharm Limited (AU:CYC)

ASX:CYC

CYC

Cyclopharm Limited

RESEARCH TOOLSreports

Cyclopharm Limited (CYC) Price & Analysis

Compare

17 Followers

CYC Stock Chart & Stats

AU$0.98

-AU$0.04(-1.82%)

At close: Jan 09 4:00 PM EST

AU$0.98

-AU$0.04(-1.82%)

Day’s Range― - ―

52-Week RangeAU$0.56 - AU$1.48

Previous CloseN/A

Volume20.15K

Average Volume (3M)97.64K

Market Cap

AU$90.60M

Enterprise ValueAU$98.90M

Total Cash (Recent Filing)AU$6.63M

Total Debt (Recent Filing)AU$14.92M

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding120,802,630

10 Day Avg. Volume155,345

30 Day Avg. Volume97,642

Financial Highlights & Ratios

PEG Ratio-0.27

Price to Book (P/B)3.98

Price to Sales (P/S)3.34

P/FCF Ratio-5.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)AU$47.80M

Bulls Say, Bears Say

Bulls Say

Recurring Consumable RevenueCyclopharm's primary revenue model is recurring consumable sales tied to each patient study. This creates predictable, volume-linked revenue that compounds as the installed base and procedure volumes grow, supporting durable demand and revenue visibility over the medium term.

Consistent Top-line GrowthSteady revenue expansion through 2025 indicates real commercial traction and wider clinical adoption of Technegas. Persistent top-line growth supports scale for consumable sales and provides a foundation to improve unit economics if cost control or pricing initiatives are implemented.

Equity Cushion Supports OperationsA ~27.1m equity base gives Cyclopharm a material cushion to absorb ongoing losses and fund near-term operations. That capital buffer reduces immediate insolvency risk and provides time to execute commercial or cost actions to stabilise fundamentals over the next several quarters.

Bears Say

Negative Gross Profit In 2025A negative gross profit is a structural red flag: it shows core product costs and delivery currently exceed revenue, undermining margin sustainability. Unless unit costs fall or pricing improves, the business cannot leverage revenue growth into profits, pressuring long-term viability.

Persistent Cash BurnDeep, persistent operating and free cash outflows force reliance on external financing or equity raises. This constrains investment in distribution, product support, or margin improvement initiatives and increases dilution or refinancing risk, harming strategic flexibility.

Rising LeverageMaterial debt growth alongside declining equity raises leverage and interest burden, increasing financial vulnerability. Higher leverage narrows headroom for setbacks, elevates refinancing risk, and can limit the company's ability to invest in expanding the installed base or supporting customers.

Cyclopharm Limited News

Cyclopharm lodges updated ASX corporate governance statement for 2025

Cyclopharm Limited ( ($AU:CYC) ) just unveiled an announcement. Cyclopharm Limited has lodged its latest corporate governance statement...

3d ago

CYC

Cyclopharm Showcases Global Reach and 2025 Performance in Annual Report

Cyclopharm Limited ( ($AU:CYC) ) has shared an update. Cyclopharm Limited has released its 2025 annual report, outlining...

3d ago

CYC

Cyclopharm Wins Multi-Site Technegas Deal with Northwestern Medicine

Cyclopharm Limited ( ($AU:CYC) ) has provided an update. Cyclopharm Limited has signed a multi-site agreement with Northwestern...

6d ago

CYC

Cyclopharm Wins 11-Site Technegas Deal with University of Pennsylvania Health System

The latest announcement is out from Cyclopharm Limited ( ($AU:CYC) ). Cyclopharm has secured a multi-site agreement with...

7d ago

CYC

Cyclopharm Director Increases Indirect Shareholding via Share Purchase Plan

Cyclopharm Limited ( ($AU:CYC) ) has shared an announcement. Cyclopharm Limited has disclosed a change in director Kevin...

18d ago

CYC

Cyclopharm Director Increases Shareholding via Share Purchase Plan

Cyclopharm Limited ( ($AU:CYC) ) just unveiled an announcement. Cyclopharm has disclosed a change in the shareholding of...

18d ago

CYC

Cyclopharm Director Increases Stake via Share Purchase Plan

The latest update is out from Cyclopharm Limited ( ($AU:CYC) ). Cyclopharm director Dianne Margaret Angus has increased...

18d ago

CYC

Cyclopharm Director Increases Stake via Share Purchase Plan

Cyclopharm Limited ( ($AU:CYC) ) has issued an announcement. Cyclopharm Limited has disclosed a change in director James...

18d ago

CYC

Cyclopharm director increases stake via Share Purchase Plan

The latest announcement is out from Cyclopharm Limited ( ($AU:CYC) ). Cyclopharm Limited has disclosed a change in...

18d ago

CYC

Cyclopharm Seeks ASX Quotation for 192,097 New Shares

Cyclopharm Limited ( ($AU:CYC) ) has provided an update. Cyclopharm Limited has applied to the ASX for quotation...

18d ago

CYC

CYC FAQ

What was Cyclopharm Limited’s price range in the past 12 months?

Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.48 in the past 12 months.

What is Cyclopharm Limited’s market cap?

Cyclopharm Limited’s market cap is AU$90.60M.

When is Cyclopharm Limited’s upcoming earnings report date?

Cyclopharm Limited’s upcoming earnings report date is Sep 01, 2026 which is in 155 days.

How were Cyclopharm Limited’s earnings last quarter?

Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.

Is Cyclopharm Limited overvalued?

According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyclopharm Limited pay dividends?

Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here

What is Cyclopharm Limited’s EPS estimate?

Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyclopharm Limited have?

Cyclopharm Limited has 120,802,630 shares outstanding.

What happened to Cyclopharm Limited’s price movement after its last earnings report?

Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.

Which hedge fund is a major shareholder of Cyclopharm Limited?

Currently, no hedge funds are holding shares in AU:CYC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cyclopharm Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-54.48%

Trailing 12-Months

Asset Growth

-25.80%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cyclopharm Limited

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.